CURRICULUM VITAE

JOHN J. BRENDESE, MD, FACR
Email: jbrendese@jmmcri.com
Tel: 704-248-8577
Fax: 704-780-4284
www.jmmcri.com

MEDICAL PRACTICE:

Joint & Muscle Medical Care/
Joint & Muscle Research Insitute
332 Lillington Ave
Charlotte, NC 28204

Ballantye Rheumatology
8840 Blakeney Proessional Drive.
Charlotte NC 28277

EDUCATION:

2002- 2004	Allergy, Immunology and Rheumatology Fellowship, Baylor College of Medicine, Houston, TX
2003	Clinical Scientist Training Program Fundamentals of Clinical Investigation Course, Baylor College of Medicine, Houston, TX
2002	Graduate School Immunology Course, Baylor College of Medicine, Houston, TX
2000-2002	Rheumatology Fellowship, State University of New York at Stony Brook, Stony Brook, NY
1998-2000	Internal Medicine Residency- Greenwich Hospital, Greenwich, CT
1996-1998	Radiology Residency- Albany Medical Center, Albany, NY
1995	Medical Degree- New York Medical College, Valhalla, NY
1989	Bachelor in Science, Electrical Engineering, Rensselaer Polytechnic Institute, Troy, NY

PROFESSIONAL EXPERIENCE:

February 2011-Present	Joint and Muscle Research Institute 332 Lillington Ave. Charlotte, NC 28204

February 2011-Present	Joint and Muscle Medical Care 332 Lillington Ave. Charlotte, NC 28204
February 2011-Present	Ballantyne Rheumatology 8840 Blakeney Professional Drive, Suite101 Charlotte, NC 26277
2005-January 2011	Suncoast Medical Clinic St. Petersburg, FL

BOARD CERTIFICATIONS:

2005 and 2015	American Board of Rheumatology
2000	American Board of Internal Medicine

MEMBERSHIPS:

2002-Present	American College of Rheumatology
2002-Present	American Academy of Allergy, Asthma and Immunology
2002-Present	American Medical Association
2001-2002	Yale Club

MEDICAL LICENSE:

- **2006-current** North Carolina
- **2004 – current** Florida
- **1999-current** New York

HONORS AND AWARDS:

2004	FIT Travel Award and Chrysalis Mentor, 61st Annual Meeting of American Academy of Allergy, Asthma and Immunology
2003	Chrysalis Mentor, 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology
2002	Fellow Reporter Scholarship Program 66th, Annual Meeting of the American College of Rheumatology

PUBLICATIONS:

Yang,Y, Xiong, Z., Zang, S., Yan,Y., Nguyen, J., NG, B., Lu,H., Brendese, J., Yang, F., Wang, H., Yang, X.F.(2005) Bel-xL Inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem.J. 392, 132-143.

RESEARCH EXPERIENCE:

SUB- INVESTIGATOR:

MULTI-INDICATION STUDY

1. *Viela Bio.*
   - **Protocol: VIB7734** A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

LUPUS STUDIES

1. *Eli Lilly :*
   - **Protocol: H9B-MC-BCDX-** A phase 3b, multicenter, open label study to evaluate the long term safety and efficacy of subcutaneous LY2127399 in patients with systemic Lupus Erythematosus (SLE)
   - **Protocol: H9B-MC-BCDT -** A Phase 3 Multicenter Randomized Double-Blinded Placebo-Controlled study to evaluate the efficacy and safety of subcutaneous LY2127399 in patients with systemic Lupus Erythematosus
   - **Protocol: I4V-MC-JAIA** - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

2. *UCB:*
   - **Protocol: SL0010- BAF** - Phase 3 randomized, double blind, placebo controlled, efficacy and safety of four 12 week treatment cycles (48 weeks total) of Epratuzumab in moderate to severe SLE.

3. *Pfizer:*
   - **Protocol: B0151006** - A double-blinded randomized, placebo-controlled multicenter dose ranging study to evaluate the efficacy and safety of PF-04236921 in subjects with Systemic Lupus Erythematosus (SLE)

4. *Medimmune:*
   - **Protocol: CD-IA-MEDI-546-1013 -**A Phase 2, Randomized Study to Evaluate the efficacy and safety of MEDI-546 in subjects with systemic Lupus Erythematosus

5. **GlaxoSmithKline**
   - **Protocol: HGS1006-C1113 -** A randomized, double blinded, placebo controlled 52-week study to assess adverse events of special interest in adults with active, autoantibody-positive Systemic Lupus Erythematosus receiving Belimumab.
   - **Protocol: 205646 | BLISS BELEIVE-** A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE)

6. ***Bristol Myers Squibb***
   - **Protocol: IM128027 -** A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus

- **Protocol: IM011021**- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus

7. ***Janssen Research & Development***
   - **Protocol: NOCOMPOUNDLUP0001;** Phase 0 Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
   - **Protocol: CNTO12755SLE3001 (Priniciple Investigator)** - Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus

8. ***AstraZeneca***
   - **Protocol: D3461C00005:** A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
   - **Protocol: D3461C00009**: A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
   - **Protocol: D3461C00008** – A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in Adult Systemic Lupus Erythematosus Subjects with Type I Interferon test high result and active skin manifestations

9. ***Biogen***
   - **230LE201-** A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

10. **Boston Pharmaceutical**
    - **BOS161721** - A Randomized Double-Blind Phase 1b/2 combined staggered multiple dose escalation study of BOS161721 in Systemic Lupus Erythematosus (SLE) patients on a background of limited standard of care

11. **Idorsia**
    - **Protocol ID-064A202** - A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE

ANKYLOSING SPONDYLITIS

1. ***Eli Lilly***
   - **Protocol: I1F-MC-RHAO(a)-** Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylosing Spondylitis

2. ***Pfizer***
   - **Protocol: A321119 -** A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Tofacitinib in Subjects with Active Ankylosing Spondylitis (AS)

3. ***Novartis***
   - ***Protocol:*** **CAIN457H2315** - A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

PSORIATIC ARTHRITIS

1. ***Eli Lilly***
   - ***Protocol*** **- I1F-MC-RHAP** - A multicenter, Randomized, Double Blinded Active and Placebo-Controlled 24 Week study followed by long term evaluation of efficacy and safety of Ixekizumab (LY2439821) in Biologic disease modifying antirheumatic drug naive patients with active Psoriatic Arthritis

2. ***ABBVIE***
   - **Protocol M14-197** - A Phase 2 Study to Investigate the Safety,Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate

3. ***AMGEN***
   - ***Protocol 20130207*** - Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis

4. **CELGENE**
   - A Phase 4, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel-group Study to evaluate the efficacy and safety Of Apremilast (CC-10004) in subjects with Early, oligoarticular Psoriatic Arthritis Despite initial stable treatment with Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD.

RHEUMATOID ARTHRITIS:

1. ***Astrazeneca***
   - ***OSKIRA-2*** – A Phase III, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs.
   - ***OSKIRA-3*** – A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patient with Inadequate Response to a TNF-alpha antagonist.
   - ***OSKIRA-4:*** A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Monotherapy with Fostamatinib Disodium in Rheumatoid Arthritis Patient with RA.
   - ***OSKIRA-X:*** **Protocol - OSKIRA-X:** A long term Extension Study to assess the safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

2. ***Amgen***
   - ***Protocol 20110186*** -A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis

3. ***Abbvie***
   - **Protocol: M14-465 -** A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
   - **Protocol: M13-542 -** A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

4. **Gilead**
   - **Protocol: GS-US-417-0302-** A Randomized, Double-blind, Placebo-controlled, Multicenter,Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
   - **Protocol: GS-US-417-0303-** A Randomized, Double-blind, Placebo-controlled, Multicenter,Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are Naïve to MTX Therapy
   - **Protocol: GS-US-417-0304** - A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

SCLERODERMA

1. ***Roche***
   - **Protocol WA29767:** A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to assess the efficacy and safety of Tocilizumab versus Placebo in patients with Systemic Sclerosis

VACCINATION AND SAFETY IN RA:

1. ***Roche***
   - **Protocol WA25204 | ENTRACTE** - A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA).

LUPUS NEPHRITIS

1. ***Aurinia***
   - **Protocol :** AUR-VCS-2012-01-A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis
   - **Protocol:** AUR-VCS-2016-01 **(Aurora) -** A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (Voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

OSTEOARTHRITIS:

1. ***Axsome***
   - ***Protoco: AXS02-K301*-COAST-1:** Clinical Knee Osteoarthritis Symptom Treatment 1 Study A Randomized, Double-blind, Placebo-controlled Trial to Assess the efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions.

OSTEOPOROSIS

1. ***Amgen***
   - ***Protocol:* 20150120 -** A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab via Prefilled Syringe

SJÖGREN'S

1. **Bristol Myers Squibb**
   - ***Protocol: IM101-603* -** A Phase 3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome
2. **Gilead**
   - **Protocol: GS-US-445-4189 -** A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren's Syndrome

REGISTRIES:

1. **SUNSTONE** – A Long Term Study of the Safety of Rituxan in Patients with Rheumatoid Arthritis after an Inadequate Response to previous Anti-TNF Therapy (5 year study completed).

2. **CORRONA** (Consortium of Rheumatology Research of North America): Data that identifies patient's responses to particular treatments or treatment combinations.

3. **CORRONA CERTAIN**: Consortium of Rheumatology Research of North America): Data that identifies patient's responses to particular treatments or treatment combinations. Initiation of a biologic agent is followed in patients fulfilling RA diagnostic criteria

4. **CORRONA PSA/SPA** - Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry

5. **Sable - HGS1006-C1124 -** A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA (belimumab)

OTHER

2003-2004	Rheumatoid Arthritis after and Inadequate Response to previous Anti-TNF Therapy. Analyze the effects of TNF-alpha on T cell markers on peripheral blood lymphocytes in normal and rheumatoid arthritis patients.
2002	Studied behavior in patients with chronic fatigue syndrome, using a step counter or actigraph to evaluate the high and low functioning behavior in each group.

My signature verifies that the information on this curriculum vitae is accurate and updated annually.

John J. Rendon

Investigator's Signature

1/4/19

Date